JCR Pharmaceuticals Co., Ltd.
4552.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥59,931,570 | ¥104,823,929 | ¥175,646,800 | ¥279,236,938 |
| - Cash | ¥13,196,000 | ¥18,756,000 | ¥13,278,000 | ¥30,733,000 |
| + Debt | ¥38,105,000 | ¥23,300,000 | ¥22,800,000 | ¥18,100,000 |
| Enterprise Value | ¥84,840,570 | ¥109,367,929 | ¥185,168,800 | ¥266,603,938 |
| Revenue | ¥33,072,000 | ¥42,871,000 | ¥34,343,000 | ¥51,082,000 |
| % Growth | -22.9% | 24.8% | -32.8% | – |
| Gross Profit | ¥21,548,000 | ¥31,251,000 | ¥25,457,000 | ¥40,621,000 |
| % Margin | 65.2% | 72.9% | 74.1% | 79.5% |
| EBITDA | -¥2,885,000 | ¥10,528,000 | ¥7,453,000 | ¥21,394,000 |
| % Margin | -8.7% | 24.6% | 21.7% | 41.9% |
| Net Income | -¥4,758,000 | ¥5,507,000 | ¥3,772,000 | ¥14,507,000 |
| % Margin | -14.4% | 12.8% | 11% | 28.4% |
| EPS Diluted | -38.43 | 43.92 | 30.22 | 116.79 |
| % Growth | -187.5% | 45.3% | -74.1% | – |
| Operating Cash Flow | -¥5,486,000 | ¥9,312,000 | -¥5,500,000 | ¥9,289,000 |
| Capital Expenditures | -¥9,888,000 | -¥2,095,000 | -¥8,560,000 | -¥11,333,000 |
| Free Cash Flow | -¥15,374,000 | ¥7,217,000 | -¥14,060,000 | -¥2,044,000 |